We observed higher CD8 + T cell infiltration, immune checkpoint expression and exhausted T cells after treatment. From these six patients, four had triple-negative ILC (TN-ILC).
Four of 23 evaluable patients had a partial response (17%), and 2 had stable disease, resulting in a clinical benefit rate of 26%.
#Flowjo free trial trial
In the phase II GELATO trial ( NCT03147040), patients with metastatic ILC were treated with weekly carboplatin (area under the curve 1.5 mg ml –1 min –1) as immune induction for 12 weeks and atezolizumab (PD-L1 blockade triweekly) from the third week until progression. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between immune checkpoint blockade and platinum was observed. Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking.
Nature Cancer volume 4, pages 535–549 ( 2023) Cite this article PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
0 kommentar(er)
